BioSpectrum the business of Bio & Health Sciences ASIA EDITION

PolarityTE appoints new CFO

June 21, 2018 | News

PolarityTE announces Paul Mann as the new Chief Financial Officer of the Company. Most recently, Mr. Mann served as the Healthcare Portfolio Manager at Highbridge Capital Management.



Singapore- PolarityTE announced that Paul Mann of Highbridge Capital Management is the new Chief Financial Officer of the Company effective July 1, 2018. Mr. Mann has nearly 20 years of financial industry experience, most recently as the Healthcare Portfolio Manager at Highbridge Capital Management. Prior to Highbridge, Mr. Mann held positions with Soros Fund Management, UBS Investment Group, Morgan Stanley and Deutsche Bank. Notably, Mr. Mann began his career as a scientist at Proctor and Gamble and is named as an inventor on patent applications for skincare compounds and technologies. Mr. Mann has an MA (Cantab) and an MEng from Cambridge University where he studied Natural Sciences and Chemical Engineering. He is a CFA charterholder.

“Paul is brilliant. From basic science, to healthcare, to corporate strategy, to financial markets—he is simply brilliant,” said Denver M. Lough, MD, PhD, Chairman and Chief Executive Officer of PolarityTE. “This decision to bring Paul onto the Polarity team was easy. His knowledge and experience across the field is phenomenal and his strategic global vision of the market is precisely suited for the Company as we continue to recruit experienced management, clinical and operational talent to further position the Company for growth. We sincerely look forward to an incredible future with him and the new strategic arm, PolarityIS. John Stetson has played a key role in building the company from its inception and we are thrilled to have him serve as Chief Investment Officer and lead PolarityIS, which will focus on driving value through strategic ventures and the monetization of our derivative technologies.”